Brief: Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln
12/01/2026 19:19
Jan 12 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVENUES SAREPTA THERAPEUTICS Q4 REVENUE USD 369.6 MILLION VS. IBES ESTIMATE USD 351.7 MILLION SAREPTA THERAPEUTICS INC - Q4 NET PRODUCT REVENUE FOR ELEVIDYS TOTALED $110.4 MLN SAREPTA THERAPEUTICS INC: RECONFIRM YEARLY SALES FLOOR FOR ELEVIDYS OF $500.0 MLN Source text: ID:nBw3ZlYCqa Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure